ACCEL DIAGNOSTICS, LLC
Houston, TX · Medtech · Private
RapidQCT, a quantitative point-of-care serological blood test that measures COVID-19 antibody titers
acceldx.com →- Grants
- $4.9M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $937K
- 2 awards · Health and Human S
- #328 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A disposable assay for the monitoring of heart failure in the home setting | $225,133 | |
| Federal grant | Department of Health and Human Services · Phase I · A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood | $145,499 | |
| Federal grant | Department of Health and Human Services · Phase I · I Corps Program for A rapid instrument free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood | $194,545 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf SBIR Topic #97 - Phase I - Minimally Invasive Test For Chemotherapy-induced Cardiotoxicity | $212,552 | |
| Federal grant | Department of Health and Human Services · Phase I · I-Corps Program for A rapid instrument-free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood. | $49,046 | |
| Federal grant | Department of Health and Human Services · Phase II · A disposable assay for the monitoring of heart failure in the home setting. | $943,624 | |
| Federal grant | Department of Health and Human Services · Phase II · A disposable assay for the monitoring of heart failure in the home setting. | $331,659 | |
| Federal contract | Department of Health and Human Services · SBIR Topic 97 - Phase II - Early Detection And Monitoring Of Cardiac Injury Due To Cardiotoxicity | $724,602 | |
| Federal grant | Department of Health and Human Services · Phase I · A Rapid Non-Invasive Device for Monitoring Preeclampsia in High Risk Pregnancy | $215,450 | |
| Federal grant | Department of Health and Human Services · Phase I · A rapid blood test to aid the triage of patients affected by head injuries. | $223,966 | |
| Federal grant | Department of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $240,405 | |
| Federal grant | Department of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $1,060,897 | |
| Federal grant | Department of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $97,316 | |
| Federal grant | Department of Health and Human Services · Phase II · A COVID-19 Point of Care Serological Assay for Rapid Quantification of Antibody Titer. | $398,753 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 325 | Xoran Technologies LLC | $957K | — |
| 326 | Flashback Technologies, Inc. | $950K | $8.0M |
| 327 | Neuroptics, Inc. | $945K | $2.3M |
| 328 | ACCEL DIAGNOSTICS, LLC | $937K | — |
| 329 | AUTONOMOUS HEALTHCARE INC. | $925K | — |
| 330 | VITRUVIAN BIO, LLC | $900K | — |
| 331 | COVARIS, INC. | $900K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.